Using Tacrolimus in Living Donor Liver Transplantation Recipients with High Model for End-stage Liver Disease Scores Might Increase the Risk of Postoperative Neuropsychologic Deficits.
出版信息
Pak J Med Sci. 2013 Jul;29(4):1085-6. doi: 10.12669/pjms.294.3797.
Abstract
摘要
相似文献
1
Using Tacrolimus in Living Donor Liver Transplantation Recipients with High Model for End-stage Liver Disease Scores Might Increase the Risk of Postoperative Neuropsychologic Deficits.
Pak J Med Sci. 2013 Jul;29(4):1085-6. doi: 10.12669/pjms.294.3797.
2
Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
Liver Transpl. 2002 Mar;8(3):212-8. doi: 10.1053/jlts.2002.31346.
3
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
Clin Pharmacol Ther. 2006 Oct;80(4):331-45. doi: 10.1016/j.clpt.2006.06.008.
4
Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
Liver Transpl. 2005 Nov;11(11):1395-402. doi: 10.1002/lt.20508.
5
Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients.
Liver Transpl. 2002 Mar;8(3):219-23. doi: 10.1053/jlts.2002.30885.
6
Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
Transplantation. 2012 Oct 27;94(8):866-72. doi: 10.1097/TP.0b013e318263700a.
7
Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
Liver Transpl. 2003 Jul;9(7):737-40. doi: 10.1053/jlts.2003.50122.
8
Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era.
Ann Surg. 2013 Aug;258(2):306-11. doi: 10.1097/SLA.0b013e3182754b8e.
9
Live donor liver transplantation in high MELD score recipients.
Ann Surg. 2010 Jan;251(1):153-7. doi: 10.1097/SLA.0b013e3181bc9c6a.
10
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.
本文引用的文献
1
Predictive factors of early graft loss in living donor liver transplantation.
Arq Gastroenterol. 2012 Apr-Jun;49(2):157-61. doi: 10.1590/s0004-28032012000200011.
2
A high model for end-stage liver disease score should not be considered a contraindication to living donor liver transplantation.
Transplant Proc. 2012 Mar;44(2):316-9. doi: 10.1016/j.transproceed.2012.02.006.
3
Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation.
Psychiatry Clin Neurosci. 2006 Apr;60(2):174-81. doi: 10.1111/j.1440-1819.2006.01483.x.
4
A model to predict the development of mental status changes of unclear cause after liver transplantation.
Liver Transpl. 2003 Dec;9(12):1312-9. doi: 10.1016/j.lts.2003.09.023.
5
Application of a continuous disease severity score to the OPTN liver waiting list.
Clin Transpl. 2001:19-24.
6
Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone.
J Hepatol. 1994 Oct;21(4):572-7. doi: 10.1016/s0168-8278(94)80103-7.
Zotero 插件